K-numberK252648
Device nameNiti-S SPAXUS Stent
ApplicantTaewoong Medical Co., Ltd.
Product codePCU
Device classClass II
Decision dateMar 13, 2026
DecisionSubstantially Equivalent
Regulation876.5015
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Niti-S SPAXUS Stent is a fully covered, self-expanding metallic stent made from nitinol with a silicone coating, designed for endoscopic drainage of pancreatic pseudocysts, walled-off necrosis, and gallbladder collections. The stent features a bi-flange design for stable positioning, radiopaque markers for fluoroscopic visualization, and is delivered via a non-electrocautery disposable delivery system. It is intended for implantation up to 60 days and should be removed upon confirmation of resolution.

Technological characteristics

The Niti-S SPAXUS uses a standard delivery system requiring auxiliary tools (versus the AXIOS predicate which offers both standard and electrocautery-enhanced delivery). Both devices employ nitinol with silicone coating, are MR Conditional, use ethylene oxide sterilization, and are provided sterile for single-patient use. The SPAXUS offers stent sizes of 8mm × 20mm, 10mm × 20mm, and 16mm × 20mm (total length), compared to the AXIOS's various saddle-length configurations (6mm × 8mm to 20mm × 10mm).

Test standards cited

Not stated in this summary. The document references ISO 13485 (Design controls, Nonconforming product, Corrective and preventative action) in compliance sections but does not cite specific consensus standards for device testing.

Substantial equivalence argument

Substantial equivalence is based on identical intended use (pancreatic and gallbladder drainage) and nearly identical technological characteristics—both use nitinol with silicone coating, MR Conditional design, and ethylene oxide sterilization. Biocompatibility and delivery system materials are identical to previously cleared devices (Niti-S Biliary Stent K240522 and Esophageal TTS Stent K240522). Clinical data from a 35-patient prospective study showed 97.1% success with no device-related serious adverse events, supported by three meta-analyses demonstrating comparable or superior safety and efficacy to the AXIOS predicate.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →